Client Reference No.: SF03-057

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jack TAUNTON, et al.

U.S. Application No.: 10/552,847

Int'l Application No.: PCT/US04/011297

Int'l Filing Date: April 12, 2004

For: SELECTIVE SERINE/

THREONINE KINASE INHIBITORS

Confirmation No.: 2596

Examiner: Not Yet Assigned

Art Unit:

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references, in compliance with the requirements of 37 CFR §1.98(a)(2), are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the

undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Joel G. Ackerman Reg. No. 24,307

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300 JA:sba

60793114 v1

Substitute for form 1449A&B/PTO				Complete if Known		
				Application Number	10/552,847	
INFORMATION DISCLOSURE				Filing Date	April 12, 2004	
STATEMENT BY APPLICANT			ANT	First Named Inventor	TAUNTON, Jack	
				Art Unit	1624	
	(Use as many shee	ts as necessary)		Examiner Name	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
Sheet	1	of	2	Attorney Docket Number	018062-006210US	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ^{2 (# Angwin)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/BK/	AA	US 5,844,106	12-01-1998	Seela et al.		
	AB	US 2002/0013354 A1	01-31-2002	Cheng et al.	·	
	AC	US 6,376,527 B1	04-23-2002	Goldstein et al.		
	AD	US 2002/0103245 A1	08-01-2002	Goldstein et al.		
1/	AE	US 2002/0156114 A1	10-24-2002	Goldstein et al.		
V	AF	US 2003/0018051 A1	01-23-2003	Goldstein et al.		

	FOREIGN PATENT DOCUMENTS							
Examiner	No.¹			Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages		
Initials* N		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T⁵
/BK/	AG	wo	99/06396	A1	02-11-1999			
. 80	АН	wo	97/38983	A1	10-23-1997			
W	Al	wo	00/31048	A1	06-02-2000			

	NON PATENT LITERATURE DOCUMENTS							
	ıminer tials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
/E	3K/	AJ	ABIRU, Seigou et al.; "Aspirin and NS-398 Inhibit Hepatocyte Growth Factor-Induced Invasiveness of Human Hepatoma Cells"; 2002, <u>Hepatology</u> , Vol. 35, No. 5, pp. 1117-1124.					
		AK	BURCHAT, A.F., et al.; "Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick II"; <u>Bioorganic & Medicinal Chemistry Letters</u> ; October 2, 2000; pp. 2171-2174; Vol. 10, No. 19.					
		AL	CHENON, M.T., et al.; "Carbon-13 magnetic resonance. XXV. Basic set of parameters for the investigation of tautomerism in purines established from carbon-13 magnetic resonance studies using certain purines and pyrrolo[2,3-d]pyrimidines.; <u>Journal of the American Chemical Society</u> ; 1975; pp. 4627-4636; Vol. 97, No. 16.					
S. S	/	АМ	DAVE, Chaitanya G. et al.; "Synthesis & Biological Activity of Pyrrolo[2,3-d]pyrimidines"; 1988, Indian Journal of Chemistry, Vol. 27B, pp. 778-780.					

Examiner Signature	/Bruck Kifle/ (04/25/2008)	Date Considered	04/25/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known		
				Application Number	10/552,847	
INFORMATION DISCLOSURE				Filing Date	April 12, 2004	
STA	STATEMENT BY APPLICANT			First Named Inventor	TAUNTON, Jack	
				Art Unit	1624	
	(Use as many sheet	s as necessary)		Examiner Name	Net-Vet-Accigned Kifle	
Sheet	2	of	2	Attorney Docket Number	018062-006210US	

	5.1.9	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/BK/	AN	HANKE, Jeffrey H. et al.; Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor"; 1996, The Journal of Biological Chemistry, Vol. 271, No. 2, pp. 695-701.	
000000000000000000000000000000000000000	AO	LIU, Yi et al.; "Structural basis for selective inhibition of Src family kinases by PP1"; 1999, Chemistry & Biology, Vol. 6, No. 9, pp. 671-678.	
90000000000	АР	SCHINDLER, Thomas et al.; "Crystal Structure of Hck in Complex with a Src Family- Selective Tyrosine Kinase Inhibitor"; 1999, <u>Molecular Cell</u> , Vol. 3, pp. 639-648.	
	AQ	STEVENSON, Marry Ann et al.; "Salicylic Acid and Asprin Inhibit the Activity of RSK2 Kinase and Repress RSK2-Dependent Transcription of Cyclic AMP Response Element Binding Protein- and NF- _k B-Responsive Genes"; 1999, The Journal of Immunology, pp. 5608-5616.	
8,000,000,000	AR	TATTON, Louise et al.; "The Src-selective Kinase Inhibitor PP1 Also Inhibits Kit and Bcr-Abl Tyrosine Kinases"; 2003, The Journal of Biological Chemistry, Vol. 278, No. 7, pp. 4847-4853.	
V	AS	ZHU, Xiaotian et al.; "Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors"; 1999, Structure, Vol. 7, No. 6, pp. 651-661.	

Examiner Signature /Bruck Kifle/ (04/25/2008) Date Considered	04/25/2008
---	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.